New Two-Step transplant shows promise for tough blood cancers

NCT ID NCT01315132

Completed Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to see if more than 60% of patients would survive at least one year after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclophosphamide
What this could lead to: If successful, this approach could improve survival and reduce severe graft-versus-host disease in patients with high-risk blood cancers receiving a stem cell transplant from a matched sibling.
What could go wrong: This is a small, completed phase 2 trial with only 47 participants, so results may not apply to all patients. The treatment still carries risks of infection, organ damage, and GVHD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia chronic myelogenous leukemia, BCR-ABL1 positive classic Hodgkin lymphoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Hodgkins lymphoma leukemia lymphoma myelodysplastic syndrome myeloproliferative neoplasm non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES HODGKIN'S DISEASE LEUKEMIA LYMPHOMA MULTIPLE MYELOMA

Contacts and locations

Locations

Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.